JP2005532332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532332A5 JP2005532332A5 JP2004506824A JP2004506824A JP2005532332A5 JP 2005532332 A5 JP2005532332 A5 JP 2005532332A5 JP 2004506824 A JP2004506824 A JP 2004506824A JP 2004506824 A JP2004506824 A JP 2004506824A JP 2005532332 A5 JP2005532332 A5 JP 2005532332A5
- Authority
- JP
- Japan
- Prior art keywords
- neuregulin
- composition
- functional fragment
- kit
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014413 Neuregulin Human genes 0.000 claims 54
- 108050003475 Neuregulin Proteins 0.000 claims 54
- 239000000203 mixture Substances 0.000 claims 43
- 239000012634 fragment Substances 0.000 claims 36
- 239000003814 drug Substances 0.000 claims 19
- 230000000069 prophylactic effect Effects 0.000 claims 18
- 229940124597 therapeutic agent Drugs 0.000 claims 18
- 206010047470 viral myocarditis Diseases 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 206010048610 Cardiotoxicity Diseases 0.000 claims 10
- 231100000259 cardiotoxicity Toxicity 0.000 claims 10
- 208000010125 myocardial infarction Diseases 0.000 claims 10
- 230000006870 function Effects 0.000 claims 9
- 238000004519 manufacturing process Methods 0.000 claims 9
- 239000005541 ACE inhibitor Substances 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 102000048238 Neuregulin-1 Human genes 0.000 claims 5
- 108090000556 Neuregulin-1 Proteins 0.000 claims 5
- 101800000675 Neuregulin-2 Proteins 0.000 claims 5
- 101800000673 Neuregulin-3 Proteins 0.000 claims 5
- 101800002641 Neuregulin-4 Proteins 0.000 claims 5
- 102100022668 Pro-neuregulin-2, membrane-bound isoform Human genes 0.000 claims 5
- 102100022659 Pro-neuregulin-3, membrane-bound isoform Human genes 0.000 claims 5
- 102100022658 Pro-neuregulin-4, membrane-bound isoform Human genes 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 5
- 230000000747 cardiac effect Effects 0.000 claims 5
- 230000003111 delayed effect Effects 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 206010003119 arrhythmia Diseases 0.000 claims 4
- 230000006793 arrhythmia Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 230000002861 ventricular Effects 0.000 claims 4
- 229940124629 β-receptor antagonist Drugs 0.000 claims 4
- 229940086440 Angiotensin I converting enzyme inhibitor Drugs 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002107 myocardial effect Effects 0.000 claims 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 229930003347 Atropine Natural products 0.000 claims 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 2
- 208000009525 Myocarditis Diseases 0.000 claims 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims 2
- 239000000006 Nitroglycerin Substances 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 2
- 229960000396 atropine Drugs 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- -1 cardioprotectants Substances 0.000 claims 2
- 229940045200 cardioprotective agent Drugs 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 229960003711 glyceryl trinitrate Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000003680 myocardial damage Effects 0.000 claims 2
- 235000015097 nutrients Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 2
- 229960002646 scopolamine Drugs 0.000 claims 2
- 229960000103 thrombolytic agent Drugs 0.000 claims 2
- 235000015961 tonic Nutrition 0.000 claims 2
- 230000001256 tonic effect Effects 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 241001466953 Echovirus Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000007888 Sinus Tachycardia Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 claims 1
- 231100001259 acute cardiotoxicity Toxicity 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000008828 contractile function Effects 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000003205 diastolic effect Effects 0.000 claims 1
- 230000010339 dilation Effects 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000002427 irreversible effect Effects 0.000 claims 1
- 210000005240 left ventricle Anatomy 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000005086 pumping Methods 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 229960000716 tonics Drugs 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2002/000349 WO2003099320A1 (en) | 2002-05-24 | 2002-05-24 | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| PCT/CN2003/000355 WO2003099300A1 (en) | 2002-05-24 | 2003-05-15 | Neuregulin based methods and compositions for treating cardiovascular diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010223952A Division JP5809789B2 (ja) | 2002-05-24 | 2010-10-01 | 薬学的組成物、およびキット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005532332A JP2005532332A (ja) | 2005-10-27 |
| JP2005532332A5 true JP2005532332A5 (https=) | 2006-07-06 |
Family
ID=29555543
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506824A Pending JP2005532332A (ja) | 2002-05-24 | 2003-05-15 | 心血管疾患を処置するためのニューレギュリン法および組成物 |
| JP2010223952A Expired - Lifetime JP5809789B2 (ja) | 2002-05-24 | 2010-10-01 | 薬学的組成物、およびキット |
| JP2014000319A Expired - Lifetime JP5964868B2 (ja) | 2002-05-24 | 2014-01-06 | 心血管疾患を処置するためのニューレギュリン法および組成物 |
| JP2016018132A Expired - Lifetime JP6603149B2 (ja) | 2002-05-24 | 2016-02-02 | 心血管疾患を処置するためのニューレギュリン法および組成物 |
| JP2017214721A Pending JP2018052957A (ja) | 2002-05-24 | 2017-11-07 | 心血管疾患を処置するためのニューレギュリン法および組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010223952A Expired - Lifetime JP5809789B2 (ja) | 2002-05-24 | 2010-10-01 | 薬学的組成物、およびキット |
| JP2014000319A Expired - Lifetime JP5964868B2 (ja) | 2002-05-24 | 2014-01-06 | 心血管疾患を処置するためのニューレギュリン法および組成物 |
| JP2016018132A Expired - Lifetime JP6603149B2 (ja) | 2002-05-24 | 2016-02-02 | 心血管疾患を処置するためのニューレギュリン法および組成物 |
| JP2017214721A Pending JP2018052957A (ja) | 2002-05-24 | 2017-11-07 | 心血管疾患を処置するためのニューレギュリン法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US7795212B2 (https=) |
| EP (2) | EP2606901A1 (https=) |
| JP (5) | JP2005532332A (https=) |
| CN (4) | CN100522997C (https=) |
| AU (3) | AU2002304965A1 (https=) |
| CA (1) | CA2487112C (https=) |
| ES (1) | ES2627547T3 (https=) |
| WO (3) | WO2003099320A1 (https=) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US8388672B2 (en) | 1999-08-09 | 2013-03-05 | Cardiokinetix, Inc. | System for improving cardiac function by sealing a partitioning membrane within a ventricle |
| US8529430B2 (en) | 2002-08-01 | 2013-09-10 | Cardiokinetix, Inc. | Therapeutic methods and devices following myocardial infarction |
| US10307147B2 (en) | 1999-08-09 | 2019-06-04 | Edwards Lifesciences Corporation | System for improving cardiac function by sealing a partitioning membrane within a ventricle |
| US8257428B2 (en) | 1999-08-09 | 2012-09-04 | Cardiokinetix, Inc. | System for improving cardiac function |
| US7674222B2 (en) | 1999-08-09 | 2010-03-09 | Cardiokinetix, Inc. | Cardiac device and methods of use thereof |
| US9694121B2 (en) | 1999-08-09 | 2017-07-04 | Cardiokinetix, Inc. | Systems and methods for improving cardiac function |
| US8500795B2 (en) | 1999-08-09 | 2013-08-06 | Cardiokinetix, Inc. | Retrievable devices for improving cardiac function |
| US9332992B2 (en) | 2004-08-05 | 2016-05-10 | Cardiokinetix, Inc. | Method for making a laminar ventricular partitioning device |
| US10064696B2 (en) | 2000-08-09 | 2018-09-04 | Edwards Lifesciences Corporation | Devices and methods for delivering an endocardial device |
| US9078660B2 (en) | 2000-08-09 | 2015-07-14 | Cardiokinetix, Inc. | Devices and methods for delivering an endocardial device |
| US9332993B2 (en) | 2004-08-05 | 2016-05-10 | Cardiokinetix, Inc. | Devices and methods for delivering an endocardial device |
| WO2003099320A1 (en) * | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| AU2003237367A1 (en) * | 2002-06-03 | 2003-12-19 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
| WO2007019232A2 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| US7776817B2 (en) * | 2005-09-02 | 2010-08-17 | Morehouse School Of Medicine | Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration |
| US20070213264A1 (en) * | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| JP5738516B2 (ja) | 2005-12-30 | 2015-06-24 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | 心機能改善のためのニューレグリンの徐放 |
| WO2007130724A2 (en) | 2006-02-06 | 2007-11-15 | Northwind Ventures | Systems and methods for volume reduction |
| CN101743474B (zh) * | 2007-05-10 | 2015-06-03 | 阿索尔达治疗公司 | 检测心脏损伤的方法 |
| CN103432681A (zh) * | 2007-05-25 | 2013-12-11 | 上海泽生科技开发有限公司 | 包含神经调节蛋白的药物制剂及装置 |
| CN101310766B (zh) * | 2007-05-25 | 2014-04-16 | 上海泽生科技开发有限公司 | 神经调节蛋白的新用途 |
| CN101310765A (zh) * | 2007-05-25 | 2008-11-26 | 上海泽生科技开发有限公司 | 神经调节蛋白应用于人的安全剂量 |
| US20090156488A1 (en) | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| CN102159236A (zh) * | 2008-07-17 | 2011-08-17 | 阿索尔达治疗公司 | 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂 |
| EP2328606B1 (en) | 2008-08-15 | 2016-10-05 | Acorda Therapeutics, Inc. | Compositions and methods for treatment during non-acute periods following cns neurological injury |
| EP2346526A2 (en) | 2008-09-22 | 2011-07-27 | Massachusetts Institute of Technology | Compositions of and methods of using ligand dimers |
| JP5743898B2 (ja) * | 2008-11-28 | 2015-07-01 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | ニューレグリンペプチド及びその使用 |
| JP2012509908A (ja) * | 2008-11-28 | 2012-04-26 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | ニューレグリン及び心臓幹細胞 |
| EP3087998B1 (en) | 2009-06-09 | 2019-09-04 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neuregulin based methods for treating heart failure |
| CN102470161A (zh) * | 2009-06-09 | 2012-05-23 | 上海泽生科技开发有限公司 | 神经调节蛋白用于治疗心力衰竭的有效剂量 |
| WO2011006072A2 (en) * | 2009-07-10 | 2011-01-13 | Northwestern University | Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia |
| WO2011011388A2 (en) * | 2009-07-22 | 2011-01-27 | Children's Medical Center Corporation | Neuregulin induced regeneraton of heart muscle muscle |
| JP6096262B2 (ja) * | 2009-08-25 | 2017-03-15 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | ニューレグリンに基づく心不全の治療方法 |
| JP5709880B2 (ja) * | 2009-10-23 | 2015-04-30 | アモーサイト インコーポレイテッド | 血管の機能不全による進行性心筋傷害治療のための組成物および方法 |
| AU2010315535A1 (en) | 2009-10-26 | 2012-05-03 | Cardiokinetix, Inc. | Ventricular volume reduction |
| CN103772498B (zh) * | 2009-11-09 | 2015-07-15 | 上海泽生科技开发有限公司 | 纽兰格林及其用途 |
| CN102139095A (zh) * | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| US9029328B2 (en) | 2010-03-24 | 2015-05-12 | The Brigham And Women's Hospital, Inc. | Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands |
| CN104399062A (zh) * | 2011-01-11 | 2015-03-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| WO2012119129A1 (en) | 2011-03-02 | 2012-09-07 | Berg Biosystems, Llc | Interrogatory cell-based assays and uses thereof |
| US8754044B2 (en) | 2011-05-03 | 2014-06-17 | Northwestern University | Neuroprotection by hepatic cells and hepatocyte secretory factors |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| MX375673B (es) | 2012-04-02 | 2025-03-06 | Berg Llc | Ensayos basados en interrogatorios celulares y usos de los mismos. |
| EA201492178A1 (ru) * | 2012-05-22 | 2015-12-30 | Берг Ллк | Основанные на клетках перекрестные анализы для идентификации маркеров индуцированной лекарственными средствами токсичности |
| NZ706155A (en) | 2012-09-12 | 2018-09-28 | Berg Llc | Use of markers in the identification of cardiotoxic agents |
| WO2014051567A1 (en) * | 2012-09-26 | 2014-04-03 | Morehouse School Of Medicine | Chimeric neuregulins and method of making and use thereof |
| US10894815B2 (en) | 2012-10-08 | 2021-01-19 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Compositions and methods for treating heart failure in diabetic patients |
| RU2015154737A (ru) | 2013-05-22 | 2017-06-27 | Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. | Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности |
| DE112014004537T5 (de) * | 2013-10-01 | 2016-07-21 | Kymab Limited | Tiermodelle und therapeutische Moleküle |
| BR112016007960B8 (pt) * | 2013-10-18 | 2023-11-14 | Attoquant Diagnostics Gmbh | Método para o diagnóstico de hiperaldosteronismo primário em um indivíduo |
| CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
| EP3131570A1 (en) | 2014-04-15 | 2017-02-22 | Universiteit Antwerpen | Treatment of nephropathy |
| CA2960837A1 (en) | 2014-09-11 | 2016-03-17 | Berg Llc | Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data |
| CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| RU2017114607A (ru) | 2014-09-28 | 2018-10-29 | Кардиокинетикс, Инк. | Устройства для терапии нарушений функции сердца |
| CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| EP3247380A1 (en) * | 2015-01-20 | 2017-11-29 | Universiteit Antwerpen | Neuregulin in the treatment of fibrotic disorders |
| CN104922153A (zh) * | 2015-04-02 | 2015-09-23 | 连祺周 | Nrg1-erbb4复合体在制备治疗心肌缺血的药物中的应用 |
| US10017574B2 (en) * | 2015-05-07 | 2018-07-10 | Yeda Research And Development Co. Ltd. | Methods, kits and devices for promoting cardiac regeneration |
| AU2016375964A1 (en) * | 2015-12-22 | 2018-05-17 | Société des Produits Nestlé S.A. | Methods for treating sarcopenia and frailty |
| DE102018107407A1 (de) | 2017-03-28 | 2018-10-04 | Edwards Lifesciences Corporation | Positionieren, einsetzen und zurückholen von implantierbaren vorrichtungen |
| PE20210111A1 (es) * | 2018-04-11 | 2021-01-19 | Salubris Biotherapeutics Inc | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso |
| CN111407881A (zh) * | 2019-01-07 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物 |
| AR121035A1 (es) * | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| CN109999015A (zh) * | 2019-04-24 | 2019-07-12 | 江苏省中医药研究院 | 紫草素在制备预防或治疗房颤药物中的用途 |
| AU2020348436A1 (en) | 2019-09-16 | 2022-04-07 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Recombinant human neuregulin derivatives and use thereof |
| CN110714068A (zh) * | 2019-11-14 | 2020-01-21 | 南通大学 | 膜蛋白分子ErbB4在制备治疗脑缺血损伤药物中的应用 |
| CN113289002A (zh) | 2020-02-24 | 2021-08-24 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物 |
| CN113238060B (zh) * | 2021-05-08 | 2022-10-11 | 迈克生物股份有限公司 | 用于预测或诊断心肌炎的试剂盒 |
| WO2023070078A1 (en) * | 2021-10-22 | 2023-04-27 | The Research Institute At Nationwide Children's Hospital | Neuregulin for protection against respiratory viral infection and post-viral disease |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3377363D1 (en) | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| DE3220116A1 (de) | 1982-05-28 | 1983-12-01 | Dr. Karl Thomae Gmbh, 7950 Biberach | Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS607934A (ja) | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造方法 |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| WO1989001489A1 (en) | 1987-08-10 | 1989-02-23 | Commonwealth Scientific And Industrial Research Or | Control of angiogenesis and compositions and methods therefor |
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| JPH02226533A (ja) | 1989-02-27 | 1990-09-10 | Mitsubishi Electric Corp | 情報記録媒体 |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| GB9107566D0 (en) | 1991-04-10 | 1991-05-29 | Ludwig Inst Cancer Res | Glial mitogenic factors,their preparation and use |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US7115554B1 (en) | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US5834229A (en) * | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US5367060A (en) | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
| IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| DE69324671D1 (de) | 1992-02-10 | 1999-06-02 | Interferon Sciences Inc | Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute |
| US6087323A (en) | 1992-04-03 | 2000-07-11 | Cambridge Neuroscience, Inc. | Use of neuregulins as modulators of cellular communication |
| DE4221256C2 (de) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenische Zusammensetzung für die topische Anwendung |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| FI943071L (fi) | 1993-06-24 | 1994-12-25 | Takeda Chemical Industries Ltd | Anti-endoteliiniainetta pysyvästi vapauttava valmiste |
| US5834441A (en) | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
| US5399699A (en) | 1994-01-24 | 1995-03-21 | Abbott Laboratories | Indole iminooxy derivatives which inhibit leukotriene biosynthesis |
| DK0679718T3 (da) | 1994-04-09 | 2001-10-22 | Hoffmann La Roche | Fremgangsmåde til fremstilling af alfa-interferon |
| US5770567A (en) | 1994-11-14 | 1998-06-23 | Genentech, Inc. | Sensory and motor neuron derived factor (SMDF) |
| JP3342873B2 (ja) | 1995-03-10 | 2002-11-11 | ジェネンテク・インコーポレイテッド | ｇａｓ６による受容体活性化 |
| US6750196B1 (en) | 1995-03-27 | 2004-06-15 | Acorda Therapeutics | Methods of treating disorders of the eye |
| US5741511A (en) | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
| US5714385A (en) | 1995-05-10 | 1998-02-03 | Genentech, Inc. | Media for culturing schwann cells |
| US5721139A (en) | 1995-05-10 | 1998-02-24 | Genentech, Inc. | Isolating and culturing schwann cells |
| US6033660A (en) | 1995-05-10 | 2000-03-07 | Genentech, Inc. | Method of treating a nervous system injury with cultured schwann cells |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| US5888767A (en) | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
| JP2000502682A (ja) | 1995-12-22 | 2000-03-07 | ローカルメッド インコーポレイテッド | 血管新生を促進する成長因子の局所的血管内デリバリー |
| US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US5834235A (en) | 1996-06-21 | 1998-11-10 | Health Research, Incorporated | Inferferon-α-induced protein |
| WO1998002540A1 (en) | 1996-07-12 | 1998-01-22 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| CA2257839C (en) | 1996-07-12 | 2012-10-23 | Genentech, Inc. | Gamma-heregulin |
| US6593290B1 (en) | 1996-11-01 | 2003-07-15 | Genentech, Inc. | Treatment of inner ear hair cells |
| US6156728A (en) | 1996-11-01 | 2000-12-05 | Genentech, Inc. | Treatment of inner ear hair cells |
| US20020002276A1 (en) | 1997-02-10 | 2002-01-03 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| WO1998035036A1 (en) | 1997-02-10 | 1998-08-13 | Genentech, Inc. | Heregulin variants |
| US6136558A (en) * | 1997-02-10 | 2000-10-24 | Genentech, Inc. | Heregulin variants |
| AU7727298A (en) | 1997-06-06 | 1998-12-21 | Regents Of The University Of Michigan, The | Neuregulin response element and uses therefor |
| US6121415A (en) | 1997-07-09 | 2000-09-19 | Genentech, Inc. | ErbB4 receptor-specific neuregolin related ligands and uses therefor |
| SE9703226D0 (sv) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
| JP2001519400A (ja) * | 1997-10-14 | 2001-10-23 | ケンブリッジ ニューロサイエンス インク． | ニューレグリン使用を含む治療法 |
| US6197801B1 (en) | 1998-01-14 | 2001-03-06 | Usa Doctors Products, Inc. | Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| US5962274A (en) | 1998-03-13 | 1999-10-05 | Wake Forest University | Viral vector directed to predetermined target cells |
| AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6446242B1 (en) | 1999-04-02 | 2002-09-03 | Actel Corporation | Method and apparatus for storing a validation number in a field-programmable gate array |
| US6635249B1 (en) * | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| US6933122B1 (en) | 1999-05-14 | 2005-08-23 | The Trustees Of Columbia University In The City Of New York | A-form of cytoplasmic domain of nARIA (CRD-neuregulin) and uses thereof |
| CN1138785C (zh) * | 1999-06-04 | 2004-02-18 | 周明东 | 生长因子神经调节蛋白及其类似物的新应用 |
| US6602851B1 (en) | 1999-10-08 | 2003-08-05 | Uab Research Foundation | SMDF and GGF neuregulin splice variant isoforms and uses thereof |
| US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| US7538197B2 (en) | 2000-02-11 | 2009-05-26 | Proteosys Ag | Use of neuregulin-β as an indicator and/or target |
| KR20030016233A (ko) | 2000-02-28 | 2003-02-26 | 디코드 제네틱스 이에이치에프 | 사람 정신분열증 유전자 |
| IL151375A0 (en) | 2000-02-28 | 2003-04-10 | Decode Genetics Ehf | Nucleic acid molecule containing a neuregulin-1-associated gene and polypeptides encoded thereby |
| US6544759B1 (en) | 2000-04-21 | 2003-04-08 | Yeda Research And Development Co. Ltd | Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine |
| WO2003099320A1 (en) | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| CN1498656A (zh) | 2002-11-08 | 2004-05-26 | 上海泽生科技开发有限公司 | 神经调节蛋白用于心肌梗死治疗的方法和组合物 |
| JP2004348674A (ja) * | 2003-05-26 | 2004-12-09 | Noritsu Koki Co Ltd | 領域検出方法及びその装置 |
| CN1715926B (zh) | 2004-07-02 | 2011-08-17 | 上海泽生科技开发有限公司 | 神经调节蛋白突变体的应用 |
| CN1743005A (zh) | 2004-09-02 | 2006-03-08 | 上海泽生科技开发有限公司 | Pi3－k抑制剂的新用途及组合物 |
| CN1743006A (zh) | 2004-09-02 | 2006-03-08 | 上海泽生科技开发有限公司 | Mapk抑制剂的新用途及组合物 |
| US20070213264A1 (en) * | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| JP5738516B2 (ja) * | 2005-12-30 | 2015-06-24 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | 心機能改善のためのニューレグリンの徐放 |
| US9580515B2 (en) * | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
| US20090156488A1 (en) * | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
-
2002
- 2002-05-24 WO PCT/CN2002/000349 patent/WO2003099320A1/en not_active Ceased
- 2002-05-24 AU AU2002304965A patent/AU2002304965A1/en not_active Abandoned
- 2002-09-18 WO PCT/CN2002/000664 patent/WO2003099321A1/en not_active Ceased
- 2002-09-18 AU AU2002336030A patent/AU2002336030A1/en not_active Abandoned
-
2003
- 2003-05-15 JP JP2004506824A patent/JP2005532332A/ja active Pending
- 2003-05-15 CN CNB038118661A patent/CN100522997C/zh not_active Expired - Lifetime
- 2003-05-15 CN CN2009101185220A patent/CN101491670B/zh not_active Expired - Lifetime
- 2003-05-15 CA CA2487112A patent/CA2487112C/en not_active Expired - Fee Related
- 2003-05-15 WO PCT/CN2003/000355 patent/WO2003099300A1/en not_active Ceased
- 2003-05-15 CN CN2006101543547A patent/CN1935254B/zh not_active Expired - Lifetime
- 2003-05-15 ES ES03732172.6T patent/ES2627547T3/es not_active Expired - Lifetime
- 2003-05-15 EP EP12194239.5A patent/EP2606901A1/en not_active Withdrawn
- 2003-05-15 EP EP03732172.6A patent/EP1553960B1/en not_active Expired - Lifetime
- 2003-05-15 AU AU2003238336A patent/AU2003238336B2/en not_active Expired
- 2003-05-15 CN CNA200610139361XA patent/CN101007027A/zh active Pending
-
2004
- 2004-11-24 US US10/997,167 patent/US7795212B2/en not_active Expired - Lifetime
-
2010
- 2010-09-10 US US12/879,023 patent/US8785387B2/en not_active Expired - Lifetime
- 2010-10-01 JP JP2010223952A patent/JP5809789B2/ja not_active Expired - Lifetime
-
2014
- 2014-01-06 JP JP2014000319A patent/JP5964868B2/ja not_active Expired - Lifetime
- 2014-05-06 US US14/271,198 patent/US9555076B2/en not_active Expired - Fee Related
-
2016
- 2016-02-02 JP JP2016018132A patent/JP6603149B2/ja not_active Expired - Lifetime
-
2017
- 2017-01-30 US US15/419,946 patent/US20170360889A1/en not_active Abandoned
- 2017-11-07 JP JP2017214721A patent/JP2018052957A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532332A5 (https=) | ||
| US6509154B1 (en) | Product comprising at least a double stranded RNA combined with at least an antiviral agent | |
| WO1999047158A3 (en) | Therapeutic chemokine receptor antagonists | |
| JP2020521797A5 (https=) | ||
| CN106535895B (zh) | 丁型肝炎病毒感染的治疗 | |
| WO2002085405A3 (en) | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a) | |
| FI3294283T3 (fi) | Sakubitriili-valsartaani-annostusohjelma sydämen vajaatoiminnan hoitamiseksi | |
| KR20110053327A (ko) | 텔라프레비르 투여 방식 | |
| JP2005506345A5 (https=) | ||
| CA2470731A1 (en) | Corticotropin releasing factor 2 receptor agonists | |
| JP2021514380A5 (ja) | 筋障害及び骨障害を処置するための化合物及び組成物 | |
| WO2005014032A3 (en) | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite | |
| CN113440533B (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| JP2006517520A5 (https=) | ||
| JP2013542206A (ja) | Ｃ型肝炎ウイルス感染症の新規治療 | |
| JP2005500981A5 (https=) | ||
| JP2770911B2 (ja) | 抗ウイルス医薬組成物 | |
| JP5034944B2 (ja) | インターフェロン作用物質の活性増強剤 | |
| WO2000025773A1 (en) | Pharmaceutical combination of mildronate and enalapril | |
| NZ190028A (en) | Pharmaceutical compositions containing a dibenzothiazepine | |
| Papizh et al. | EFFICACY OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN CHILDREN WITH OCULOCEREBRORENAL SYNDROME OF LOWE (LS) | |
| JPWO2022245820A5 (https=) | ||
| JP2018533570A5 (https=) | ||
| JP2024523123A (ja) | 去勢抵抗性前立腺がんの治療薬の調製におけるスタキオースの使用 | |
| JP2004155777A (ja) | Ｃ型慢性肝炎治療剤 |